Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen) Meeting Abstract
| Authors: | Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; Ho, C.; Johnson, P. C.; Joseph, A.; Khan, N.; Mi, J.; Martignetti, R.; Matasar, M. J.; Owens, C.; Ruiters, J.; Sechio, S.; Seshan, V.; Simkins, E.; Abdel-Wahab, O.; Zelenetz, A. D. |
| Abstract Title: | Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen) |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736413906107 |
| DOI: | 10.1182/blood-2021-151831 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3540 -- Hybrid meeting, also took place online -- Source: Wos |
